Clinicaltrials.gov identifier | Experimental agents | Regimen targets | Phase | Tumor type |
---|---|---|---|---|
NCT02899078 | Nivolumab + Ibrutinib | PD-1 + BTK | 1b/2 | RCC |
NCT02923531 | Nivolumab + X4P-001 | PD-1 + CXCR4 | 1b/2a | RCC |
NCT02963610* | Pembrolizumab + Lenalidomide | PD-1 + immunomodulatory | 1/2 | NSCLC |
NCT03083808 | Pembrolizumab + Docetaxel/Pemetrexed/Gemcitabine | PD-1 + Chemotherapy | 2 | NSCLC |
NCT03041181 | Nivolumab + Docetaxel | PD-1 + Chemotherapy | 2 | NSCLC |
NCT02437136 | Pembrolizumab + Entinostat | PD-1 + HDAC | 1b/2 | NSCLC and melanoma |
NCT02959437 | Pembrolizumab + Azacitidine + Epacadostat | PD-1 + Chemotherapy + IDO-1 | 1/2 | NSCLC** |
NCT03084640 | Pembrolizumab + CMP-001 | PD-1 + TLR9 | 1b/2 | melanoma |
NCT03014648 | Atezolizumab | PD-L1 | 2 | NSCLC |